血小板減少性疾病：全球市場展望、流行病學、競爭格局和市場預測報告（32個主要市場），2025-2035年

市場概覽

• 法國血小板減少性疾病市場預計將從 2025 年的 9,500 萬美元成長到 2035 年的 1.6 億美元。
• 推動市場成長的因素如下：
• 擴大血小板生成素促效劑和標靶治療的應用
• 改善慢性血小板減少性疾病的診斷和治療
• 未來的成長取決於能夠提供持續血小板反應並降低出血風險的療法。

血小板減少性疾病概述

血小板減少性疾病是一種以血小板計數異常降低為特徵的疾病，其病因包括骨髓血小板生成減少、血小板破壞和消耗增加，以及脾腫大導致的血小板儲存。臨床嚴重程度差異很大，從無症狀的實驗室觀察異常到危及生命的出血，取決於病因和血小板計數。傳統的治療方法著重於治療原發疾病，必要時提供血小板輸注等支持性治療，以及對免疫介導型血小板減少症進行免疫抑制治療。近年來，針對特定機制的治療方法不斷湧現，例如刺激血小板生成的藥物和針對特定患者血小板破壞相關免疫路徑的療法。一類新型的免疫標靶標靶藥物不斷拓展免疫介導型血小板減少性疾病的治療選擇，而正在進行的研究旨在開發更精準、特異性的治療方法。對於相關人員，血小板減少性疾病的治療正逐漸從支持治療轉向針對原發疾病的機制主導治療。

主要亮點

• 根據預測，德國血小板減少性疾病患者人數將從 2025 年的 145,075 人增加到 2035 年的 148,284 人。
• 血小板減少性疾病的特徵是血小板數量減少，這會增加出血和相關併發症的風險。
• 該疾病的負擔仍然很重，尤其是在患有慢性或治療引起的血小板減少性疾病的患者中。
• 目前仍有大量未被滿足的需求，即開發既能提高安全性又能持續恢復血小板計數的治療方法。

市場定義：

• 北美洲（美國、加拿大）
• 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
• 中東（沙烏地阿拉伯、阿拉伯聯合大公國、科威特、土耳其）
• 亞太地區（澳洲、中國、香港、印度、印尼、日本、馬來西亞、紐西蘭、菲律賓、新加坡、韓國、台灣、泰國、越南）
• 非洲（埃及、奈及利亞、南非、摩洛哥）
• 南美洲/拉丁美洲（阿根廷、巴西、智利、哥倫比亞、墨西哥、秘魯）

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 我們如何最佳化在 32 個市場（北美、歐洲、中東、亞太、非洲和南美/拉丁美洲）的藥物開發和生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物獲得批准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• 北美洲（美國、加拿大）
• 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
• 中東（沙烏地阿拉伯、阿拉伯聯合大公國、科威特、土耳其）
• 亞太地區（澳洲、中國、香港、印度、印尼、日本、馬來西亞、紐西蘭、菲律賓、新加坡、韓國、台灣、泰國、越南）
• 非洲（埃及、奈及利亞、南非、摩洛哥）
• 南美洲/拉丁美洲（阿根廷、巴西、智利、哥倫比亞、墨西哥、秘魯）

大公司

• Qilu Pharmaceutical Co., Ltd.
• Gliknik Inc.
• Sobi, Inc.
• Sanofi
• Incyte Corporation
• Jian Zhu
• Nuvig Therapeutics, Inc.
• Eli Lilly and Company
• Dizal Pharmaceuticals
• Shanghai Escugen Biotechnology Co., Ltd.
• Argenx
• CASI Pharmaceuticals, Inc.
• Amgen
• Novartis Pharmaceuticals
• Jiangsu HengRui Medicine Co., Ltd.
• Sichuan Clover Biopharmaceuticals, Inc.
• Hutchmed
• Kedrion SpA
• Takeda
• Keymed Biosciences Co., Ltd.
• Oscotec Inc.
• Alpine Immune Sciences, Inc.
• Ouro Medicines
• Chugai Pharmaceutical
• Celgene

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並正在接受藥物治療的患者族群。
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 目前主要療法－概述及關鍵意見領袖見解
• 新興療法
• 重點
• 值得關注的後期新興療法—概述、市場上市預期和關鍵意見領袖的觀點。
• 值得關注的早期管道

第6章：未滿足的需求與目標產品分析

• 尚未滿足的主要需求及其透過新興療法實現的潛力。
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Global Thrombocytopenia Market Outlook

Thelansis's "Global Thrombocytopenia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Thrombocytopenia treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Thrombocytopenia Overview

Thrombocytopenia is a condition characterized by an abnormally low platelet count that can result from reduced platelet production in the bone marrow, increased destruction or consumption of platelets, or sequestration in an enlarged spleen. Clinical severity ranges from asymptomatic laboratory findings to life-threatening bleeding, depending on the underlying cause and platelet count. Management has traditionally focused on treating the underlying disorder, providing supportive care such as platelet transfusions when needed, and using immunosuppressive therapies for immune-mediated forms. Recent advances have introduced mechanism-specific treatments, including agents that stimulate platelet production and therapies that target the immune pathways responsible for platelet destruction in selected patients. New immune-targeted drug classes continue to expand treatment options for immune-mediated thrombocytopenia, while ongoing research aims to develop more precise, cause-specific therapies. For stakeholders, thrombocytopenia reflects a field gradually shifting from supportive management toward mechanism-driven treatment tailored to the underlying disease.

Key Highlights

• In Germany, the prevalent Thrombocytopenia population is projected to increase from 145,075 in 2025 to 148,284 by 2035.
• Thrombocytopenia is characterized by low platelet counts, increasing the risk of bleeding and associated complications.
• Disease burden remains significant, particularly in patients with chronic or treatment-induced thrombocytopenia.
• Significant unmet need remains for therapies that provide sustained platelet recovery with improved safety.

Market Overview

• The France Thrombocytopenia market is projected to grow from $95M in 2025 to $160M by 2035.
• Market growth is driven by:
• Increasing adoption of thrombopoietin receptor agonists and targeted therapies
• Improved diagnosis and management of chronic thrombocytopenia
• Future growth will depend on therapies that offer durable platelet response and reduced bleeding risk.

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Companies Mentioned

• Qilu Pharmaceutical Co., Ltd.
• Gliknik Inc.
• Sobi, Inc.
• Sanofi
• Incyte Corporation
• Jian Zhu
• Nuvig Therapeutics, Inc.
• Eli Lilly and Company
• Dizal Pharmaceuticals
• Shanghai Escugen Biotechnology Co., Ltd.
• Argenx
• CASI Pharmaceuticals, Inc.
• Amgen
• Novartis Pharmaceuticals
• Jiangsu HengRui Medicine Co., Ltd.
• Sichuan Clover Biopharmaceuticals, Inc.
• Hutchmed
• Kedrion S.p.A.
• Takeda
• Keymed Biosciences Co., Ltd.
• Oscotec Inc.
• Alpine Immune Sciences, Inc.
• Ouro Medicines
• Chugai Pharmaceutical
• Celgene

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)